Related Experiment Video
Updated: May 2, 2026

Modeling Persistent Pseudomonas aeruginosa Infection in Wounded Zebrafish Larvae
Published on: June 13, 2025
Vaccines for Pseudomonas aeruginosa: a long and winding road
Gregory P Priebe1, Joanna B Goldberg
1Harvard Medical School, Boston, MA 02115, USA.
Abstract:
Despite the recognition of Pseudomonas aeruginosa as an opportunistic pathogen, no vaccine against this bacteria has come to market. This review describes the current state-of-the-art in vaccinology for this bacterium. This includes a discussion of those at risk for infection, the types of vaccines and the approaches for empirical and targeted antigen selection under development, as well as a perspective on where the field should go. In addition, the challenges in developing a vaccine for those individuals at risk are discussed.
Related Concept Videos
Atypical Pneumonia
Mechanism of Antibiotic Resistance in MRSA
Pneumonia I: Introduction
Clinical Significance of Antibiotic Resistance
Pneumonia II: Pathophysiology
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

